Richard A. Larson to Leukemia, Myeloid, Accelerated Phase
This is a "connection" page, showing publications Richard A. Larson has written about Leukemia, Myeloid, Accelerated Phase.
Connection Strength
0.422
-
Perspectives on the treatment of chronic phase and advanced phase CML and Philadelphia chromosome positive ALL(1). Leukemia. 2003 Apr; 17(4):691-9.
Score: 0.222
-
Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy. Leukemia. 2010 Jul; 24(7):1299-301.
Score: 0.091
-
Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia. Blood. 2008 Feb 15; 111(4):1834-9.
Score: 0.077
-
The relationship between secondary chromosomal abnormalities and blast transformation in chronic myelogenous leukemia. Leukemia. 1995 Apr; 9(4):628-33.
Score: 0.032